Summit Therapeutics PLC Company Profile (LON:SUMM)

About Summit Therapeutics PLC (LON:SUMM)

Summit Therapeutics PLC logoSummit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:SUMM
  • CUSIP: N/A
  • Web: www.summitplc.com/
Capitalization:
  • Market Cap: £113.02 million
  • Outstanding Shares: 61,927,000
Average Prices:
  • 50 Day Moving Avg: GBX 197.43
  • 200 Day Moving Avg: GBX 187.88
  • 52 Week Range: GBX 138.14 - GBX 269.70
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £22.98 million
  • Price / Sales: 4.92
  • Book Value: GBX 0.06 per share
  • Price / Book: 30.42
Profitability:
  • EBITDA: ($7,170,000.00)
  • Net Margins: 57.62%
  • Return on Assets: 121.57%
Misc:
  • Average Volume: 31,720 shs.
 

Frequently Asked Questions for Summit Therapeutics PLC (LON:SUMM)

What is Summit Therapeutics PLC's stock symbol?

Summit Therapeutics PLC trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

Who are some of Summit Therapeutics PLC's key competitors?

Who are Summit Therapeutics PLC's key executives?

Summit Therapeutics PLC's management team includes the folowing people:

  • Glyn Edwards, Chief Executive Officer, Executive Director
  • Erik Ostrowski, Chief Financial Officer
  • David Roblin, Chief Operating Officer, President - Research and Development
  • Ralf H. Rosskamp M.D., Chief Medical Officer
  • Frank Murdoch Armstrong, Non-Executive Chairman of the Board
  • Valerie L. Andrews, Non-Executive Director
  • Stephen J. Davies, Non-Executive Director
  • Barry J. Price Ph.D., Non-Executive Director
  • David Wurzer CPA, Non-Executive Director

How do I buy Summit Therapeutics PLC stock?

Shares of Summit Therapeutics PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Summit Therapeutics PLC's stock price today?

One share of Summit Therapeutics PLC stock can currently be purchased for approximately GBX 182.50.


MarketBeat Community Rating for Summit Therapeutics PLC (LON SUMM)
Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  220
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (LON:SUMM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Summit Therapeutics PLC (LON:SUMM)
Price Target History for Summit Therapeutics PLC (LON:SUMM)
Analysts' Ratings History for Summit Therapeutics PLC (LON:SUMM)
Show:
DateFirmActionRatingPrice TargetDetails
6/15/2017N+1 SingerReiterated RatingcorporateView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Summit Therapeutics PLC (LON:SUMM)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Summit Therapeutics PLC (LON:SUMM)
Current Year EPS Consensus Estimate: $-38.45 EPS

Dividends

Dividend History for Summit Therapeutics PLC (LON:SUMM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Summit Therapeutics PLC (LON:SUMM)
Insider Trades by Quarter for Summit Therapeutics PLC (LON:SUMM)
Insider Trades by Quarter for Summit Therapeutics PLC (LON:SUMM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/17/2015Valerie AndrewsInsiderBuy10,500GBX 145£15,225
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Summit Therapeutics PLC (LON:SUMM)
Latest Headlines for Summit Therapeutics PLC (LON:SUMM)
Source:
Loading headlines, please wait.

Social

Social activity is not available for this stock.

Chart

Summit Therapeutics PLC (SUMM) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.